A major change at the top of GlaxoSmithKline’s (LSE: GSK) pharmaceutical business has been announced as part of what has been described as ‘succession processes’ at the company.
The UK group has announced that Abbas Hussain, president, Global Pharmaceuticals, has decided to step down and will leave the company later this year.
"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze